Baker's cyst
Methodology & AI Transparency ⓘ
Baker's cyst Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Baker's cyst (M71.20; Osteoarthritis, Gout & Joint Pain) utilize topical/targeted anti-inflammatory therapy [Baker's cyst M71.20] and objective Weight-Bearing Joint Radiograph [Baker's cyst M71.20] targets (Preserved joint-space width (M71.20)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Osteoarthritis, Gout & Joint Pain under ICD-10-CM M71.20 for Baker's cyst clinical workups.
- 3 Typical cash cost range: Workup highlights for Baker's cyst (M71.20): topical/targeted anti-inflammatory therapy [Baker's cyst M71.20].
- 4 Top reported side effects / signs: Objective lab/clinical target for Baker's cyst: Weight-Bearing Joint Radiograph [Baker's cyst M71.20] (Preserved joint-space width (M71.20)) and Serum Uric Acid in Baker's cyst (M71.20: (Gout Target)).
Ask our AI Specialists anything about Baker's cyst
What Is Baker's cyst?
Physicians managing Baker's cyst (M71.20; Osteoarthritis, Gout & Joint Pain) utilize topical/targeted anti-inflammatory therapy [Baker's cyst M71.20] and objective Weight-Bearing Joint Radiograph [Baker's cyst M71.20] targets (Preserved joint-space width (M71.20)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in arthritis & joints, Baker's cyst (M71.20) involves subchondral bone remodeling [Baker's cyst M71.20]. progression correlates with shifts in Weight-Bearing Joint Radiograph [Baker's cyst M71.20] (Preserved joint-space width (M71.20)).
Common Symptoms & Clinical Signs
- • Presentation of Baker's cyst (M71.20): sudden, intensely painful, in Baker's cyst (M71.20: red swollen big-toe)
- • Secondary Baker's cyst clinical sign: localized tendon or in Baker's cyst (M71.20: bursa tenderness limiting)
- • Symptom flares in Baker's cyst correlating with Weight-Bearing Joint Radiograph [Baker's cyst M71.20] deviation outside Preserved joint-space width (M71.20)
- • Functional arthritis & joints impact requiring topical/targeted anti-inflammatory therapy [Baker's cyst M71.20] evaluation (M71.20)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Baker's cyst Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M71.20 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Baker's cyst M71.20] | Preserved joint-space width (M71.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Baker's cyst (M71.20: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M71.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Baker's cyst (M71.20: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M71.20) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Baker's cyst
Treatment selection for Baker's cyst depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Baker's cyst)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety profile of upadacitinib in autoimmune joint pain (rheumatoid arthritis):: What a 2,630-Participant Study Found In the phase III clinical programme for RA, patients receiving upadacitinib had an increased risk of herpes zoster and CPK elevation versus adalimumab. Annals of the rheumatic diseases • 2021-03-15 • Phase III Randomized Trial | N = 2,630 | 96/100 | PMID 33115760 ↗ |
| Can This Approach Help? Inside the Latest Research on Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast-treated patients with baseline ModDA had higher probability of achieving cDAPSA treatment targets than patients with HDA. The Journal of rheumatology • 2022-07-15 • Phase III Randomized Trial | N = 126 | 88/100 | PMID 35428720 ↗ |
Baker's cyst Patient Community & “People Like Me” Threads
Filter Baker's cyst community threads and patient logs by age, biological sex, dosage, and treatment duration.